Forest Laboratories, Inc. Files Lawsuits against Several Companies for Infringement of Savella® Patents
September 24 2013 - 8:00AM
Business Wire
Forest Laboratories, Inc. (NYSE:FRX) and Forest Laboratories
Holdings, Ltd. (collectively, “Forest”) announced that Forest and
Royalty Pharma Collection Trust (“Royalty Pharma”) have jointly
filed lawsuits in the U.S. District Court for the District of
Delaware against several companies for infringement of U.S. Patent
No. 6,602,911 (“the ‘911 patent”), U.S. Patent No. 7,888,342 (“the
‘342 patent”), and U.S. Patent No. 7,994,220 (“the ‘220 patent”),
which relate to Forest’s SAVELLA® product. Forest licenses the ‘911
patent, the ‘342 patent, and the ‘220 patent from Royalty Pharma.
The ‘911 patent expires in January 2023, the ‘342 patent expires in
November 2021, and the ‘220 patent expires in September 2029.
The defendants named in the lawsuits include Apotex Corp.,
Hetero USA Inc., Lupin Ltd., Mylan Pharmaceuticals, Inc., Par
Pharmaceuticals, Inc., Ranbaxy Laboratories Ltd., and related
companies and subsidiaries.
Forest and Royalty Pharma received notification from these
companies that they had filed Abbreviated New Drug Applications
with Paragraph IV certifications seeking approval to market generic
versions of SAVELLA before the expiration of the ‘911 patent, the
‘342 patent, and the ‘220 patent. The aforementioned lawsuits were
commenced before the expiration of forty-five days from the date of
receipt of each notification letter.
About Forest
Laboratories
Forest Laboratories' (NYSE:FRX) longstanding global partnerships
and track record developing and marketing pharmaceutical products
in the United States have yielded its well-established central
nervous system and cardiovascular franchises and innovations in
anti-infective, respiratory, gastrointestinal and pain management
medicine. Forest’s pipeline, the most robust in its history,
includes product candidates in all stages of development across a
wide range of therapeutic areas. The Company is headquartered in
New York, NY. To learn more, visit www.FRX.com.
Except for the historical information contained herein, this
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
statements involve a number of risks and uncertainties, including
the difficulty of predicting FDA approvals, the acceptance and
demand for new pharmaceutical products, the impact of competitive
products and pricing, the timely development and launch of new
products, and the risk factors listed from time to time in Forest
Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form
10-Q, and any subsequent SEC filings. Forest assumes no obligation
to update forward-looking statements contained in this release to
reflect new information or future events or developments.
Forest Laboratories, Inc.Frank J. Murdolo, 1-212-224-6714Vice
President - Investor Relationsmedia.relations@frx.com
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Sep 2023 to Sep 2024